Back to search

Aristotle University Of Thessaloniki (AUTH)

Συσχέτιση των κύριων μεταλλάξεων του γονιδίου του παράγοντα VIII με την κλινικοεργαστηριακή εικόνα και την ανάπτυξη αναστολέων σε αιμορροφιλικά παιδιά

Abstract

dc:description

Hemophilia A is the most severe hereditary bleeding disorder. It istransmitted via X- linked recessive inheritance. People suffering from Hemophilia Apresent with total or partial deficiency of Clotting Factor VIII, which is attributed togenetic damage of Gene F8. The nature of the mutation of this gene is of paramountimportance to the severity of hemophilia. The mutation most closely associated withsevere disease is the inversion of intron 22. The clinical course of the disease ischaracterized by frequent bleeding incidents, mostly in the joints and the soft tissues.The diagnosis of hemophilia is based on the clinical signs of the patient, his familialand personal history of hemorrhagic events, and the results of laboratory tests.Treatment is performed through the administration of Factor VIII products.Unfortunately, about 30% of patients with severe disease develop antibodies –inhibitors to the administered factor VIII.The purpose of this study was to investigate the presence of intron 22mutation in pediatric patients suffering from hemophilia A and to determine whetherthere is a correlation between severity of the disease and the presence of thatmutation, and the development of Factor VIII inhibitors. The fact that no previousstudies in Greece had looked into that aspect of this disease made this study original.The experimental part of this dissertation consisted of sampling from 39children and adolescents from Northern Greece with hemophilia A, aged from 3months up to 21 years. They were being treated at the Hematology section of the 1stPediatric Clinic of the Aristotle University of Thessaloniki.Data collection for each patient included a detailed family and personalmedical history, a recording of the severity of the condition (light, moderate or severedepending on the amount of factor VIII), treatment rendered and whether there wasdevelopment of inhibitors to factor VIII.The clinical part of the study included a recording and assessment of thehemorrhagic events and the complications of the condition. The assessment ofhemophilic joint disease was performed by recording the number of target joints andthe physiotherapeutic Haemophilia Joint Health Score (HJHS). The experimental part of the study consisted of DNA sampling from 39patients. After that, detection of intron 22 inversion was achieved through subcyclingPCR.According to our results, 30.8% of the pediatric patients exhibited intron 22inversion. There was increased prevalence of intron 22 inversion (44%) in hemophilicpatients with severe disease and 20% in patients with moderate disease. Possiblecorrelations with the accompanying complications of the disease were investigated.The results showed that the mutation was present in 42.86% and 50% of patientspresenting with hematuria and osteopenia, respectively. A definite correlation wasalso observed between presence of the mutation and hemophilic joint disease, as wellas the condition of the joints, as described by the number of target joints and theHJHS.Timely preventive intervention has been shown to reduce the frequency ofbleeding episodes and accompanying complications, and has also been very importantto controlling the course of hemophilic joint disease. In the present study, in patientswith severe disease who received preventive therapy, only 25% exhibited high HJHSscores (>10).The development of Factor VIII inhibitor is still one of the most severecomplications in the treatment of Hemophilia A. Inhibitors neutralize the hemostaticeffects of the administered factor, thus causing further bleeding episodes in tissuesand joints. In our study we observed a definite correlation between inhibitordevelopment and hemophilic joint disease and the condition of the joints in thesepatients, as described by the number of target joints and the HJHS.According to the literature, race, family history of inhibitor development,early initiation of factor VIII treatment and an intensive therapeutic regimen aredefinite risk factors for the development of an inhibitor in patients with hemophilia A.However, the most important factor appears to be the type and location of mutationsin chromosome F8. In the present study, 41.6% of patients who exhibited thismutation developed an inhibitor to factor VIII.In conclusion, our results corroborate the findings that detection of intron 22inversion is important in predicting the presence of severe disease, as well as anincreased probability in the development of factor VIII inhibitor.However, it is equally important to individualize the assessment and thetreatment for each patient, as well as their follow-up. Finally, timely detection of hemophelia A patients that are at higher risk of developing an inhibitor is also veryimportant. Race, family history of inhibitor development and intron 22 inversionshould be considered as the most important risk factors for the development of factorVIII inhibitors in patients with severe hemophilia. These factors should be taken intoaccount when selecting the initiation, the nature, the dosage and the duration ofreplacement therapy.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Vagianou, Isidora
  • Βαγιάνου, Ισιδώρα

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38077

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Vagianou, Isidora; Βαγιάνου, Ισιδώρα. Συσχέτιση των κύριων μεταλλάξεων του γονιδίου του παράγοντα VIII με την κλινικοεργαστηριακή εικόνα και την ανάπτυξη αναστολέων σε αιμορροφιλικά παιδιά. Aristotle University Of Thessaloniki (AUTH), 2013. http://hdl.handle.net/10442/hedi/38077